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Abstract
The novel long-acting β2-agonist olodaterol demonstrated an acceptable safety 
proﬁ le in short-term phase II clinical studies. This analysis of four randomized, 
double-blind, placebo-controlled, parallel-group, phase III studies (1222.11, 
NCT00782210; 1222.12, NCT00782509; 1222.13, NCT00793624; 1222.14, 
NCT00796653) evaluated the long-term safety of olodaterol once daily (QD) in a 
large cohort of patients with moderate to very severe (Global initiative for chronic 
Obstructive Lung Disease 2–4) chronic obstructive pulmonary disease (COPD). The 
studies compared olodaterol (5 or 10 μg) QD via Respimat®, formoterol 12 μg twice 
daily (BID) via Aerolizer® (1222.13 and 1222.14), and placebo for 48 weeks. Patients 
continued receiving background maintenance therapy, with ~60% receiving 
concomitant cardiovascular therapy and 25% having a history of concomitant 
cardiac disease. Pre-speciﬁ ed analyses of pooled data assessed the adverse 
events (AEs) and serious AEs in the whole population, and in subgroups with 
cardiac disease, along with in-depth electrocardiogram and Holter monitoring. In 
total, 3104 patients were included in the safety analysis: 876 received olodaterol 
5  μg, 883 received olodaterol 10 μg, 885 received placebos, and 460 received 
formoterol 12 μg BID. Overall incidence of on-treatment AEs (71.2%), serious AEs 
(16.1%), and deaths (1.7%) were balanced across treatment groups. Respiratory 
and cardiovascular AEs, including major adverse cardiac events, were reported at 
similar frequencies in placebo and active treatment groups. The safety proﬁ les of 
both olodaterol 5 μg (marketed and registered dose) and 10 μg QD delivered via 
Respimat® are comparable to placebo and formoterol BID in this population, with 
no safety signals identiﬁ ed.
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Introduction
Th e novel long-acting β2-agonist (LABA) olodaterol has high β2-selectivity 
and a near full-agonist proﬁ le at β2-adrenoceptors (1,2). Phase II clinical 
studies of olodaterol in patients with chronic obstructive pulmonary disease 
(COPD) have demonstrated a 24-hour duration of action and eﬀ ective bron-
chodilation over a 24-hour dosing interval (3–5). Th ese studies also showed 
a satisfactory safety proﬁ le with up to 4 weeks of treatment for doses of up to 
20 μg olodaterol once daily. Th e data supported further investigation of the 
eﬃ  cacy and safety of 5 and 10 μg olodaterol once daily in longer-term studies 
in patients with COPD.
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Th e olodaterol phase III clinical program in COPD 
was speciﬁ cally designed to assess long-term eﬀ ects 
on lung function, symptomatic beneﬁ t, and safety in 
48-week pivotal studies, supplemented by evaluation of 
additional eﬃ  cacy parameters in 6-week studies (6–11). 
Similar adverse-event (AE) proﬁ les for olodaterol com-
pared to placebo and active comparators (tiotropium 
and formoterol) were observed in the individual studies 
within the phase III program.
Th e phase III pivotal studies were designed to permit 
evaluation of the eﬃ  cacy and safety of olodaterol in a 
population closely representative of those seen in clini-
cal practice, including patients with very severe COPD 
(Global initiative for chronic Obstructive Lung Disease 
[GOLD] 4), those receiving background pulmonary 
medication, and those with co-morbidities (12,13).
Th is article presents the results of a pre-speciﬁ ed 
pooled safety analysis of olodaterol 5  and 10 μg from 
the large database of patients in the combined phase III 
48-week olodaterol studies that formed the basis of the 
safety assessment for olodaterol registration.
Methods
Study designs
Th ere were two sets of global, replicate, phase III, mul-
ticenter, randomized, double-blind, placebo-controlled, 
parallel-group studies registered with ClinicalTrials.
gov (1222.11: NCT00782210; 1222.12: NCT00782509; 
1222.13: NCT00793624; 1222.14: NCT00796653) (Fig-
ure 1). Following an initial screening visit and 2-week 
baseline period, eligible patients were randomized to 
receive either 5 or 10 μg olodaterol once daily, formoterol 
12 μg twice daily (Studies 1222.13 and 1222.14 only; 
double-dummy studies), or placebo. Olodaterol inhala-
tion solution was delivered via the Respimat® inhaler, 
with each administration comprising two actuations, 
and formoterol was delivered via the Aerolizer® inhaler, 
with each administration comprising one actuation.
Patients
Patients were included if they: were current or ex-smok-
ers with a smoking history of >10 pack-years; were aged 
≥40 years with a diagnosis of COPD according to GOLD 
(14); had a post-bronchodilator forced expiratory vol-
ume in 1 second (FEV1) <80% of predicted normal; 
and had post-bronchodilator FEV1/forced vital capa-
city <70%. Patients continued with usual background 
maintenance therapy, other than LABAs, for the study 
duration, including long-acting muscarinic antagonists 
(LAMAs) and short-acting muscarinic antagonists 
(SAMAs), inhaled corticosteroids, and xanthines. 
Patients on LABAs were allowed to switch to SAMAs. 
All patients were provided with salbutamol for use as 
rescue medication, as needed, during the baseline, treat-
ment, and follow-up periods. Patients were also allowed 
to continue using any cardiovascular maintenance medi-
cation including both non-selective and cardio-selective 
β-blockers, providing they were taking a stable dose for 
at least 6 weeks prior to Visit 1.
Patients were excluded if they had: a history of 
asthma; myocardial infarction within 1 year of screen-
ing; unstable or life-threatening cardiac arrhythmia; 
known active tuberculosis; cystic ﬁ brosis or life-threat-
ening pulmonary obstruction; or hospitalization for 
heart failure within the past year.
Figure 1. Study design for pivotal, 48-week studies in chronic obstructive pulmonary disease.
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Th e studies were performed in accordance with the 
Declaration of Helsinki, International Conference on 
Harmonisation Harmonised Tripartite Guideline for 
Good Clinical Practice, and local regulations. Th e pro-
tocol was approved by the ethics research board of the 
respective institutions and signed, informed consent 
was obtained from all patients.
Safety end points
All randomized patients from each of the four stud-
ies who received at least one dose of treatment were 
included in the safety analysis set (the treated set). Elec-
trocardiogram (ECG), vital signs, laboratory parameters, 
and frequency of AEs and serious AEs were monitored 
throughout all four studies. Additionally, vital status 
follow-up of all prematurely discontinued patients 
was requested up to day 351 (planned ﬁ nal study visit; 
337  days on treatment plus 14 days post-treatment 
follow-up).
Frequency of AEs
AEs and serious AEs were recorded using the Medical 
Dictionary for Regulatory Activities (MedDRA) System 
Organ Class (SOC) and Preferred Terms (PTs). Th e anal-
ysis of AEs was based on treatment-emergent AEs using 
the standard deﬁ nition of those events with an onset any 
time following the ﬁ rst dose of study drug up to 12 days 
after the last study drug intake, and results were sum-
marized descriptively. In addition, speciﬁ c aggregate 
terms, Special MedDRA Query (SMQ) and a number of 
predeﬁ ned sponsor-customized MedDRA queries, were 
used to examine categories of AEs. Furthermore, the 
incidence of cardiac and vascular AEs with olodaterol 
and placebo was compared in a subgroup of patients 
with a history of cardiac disease, and in a separate 
subgroup of patients who were concomitantly taking 
β-blockers. Exposure-adjusted incidence rates for major 
adverse cardiac events (MACE) were calculated and rate 
ratios estimated for treatment comparisons of all active 
therapies versus placebo based on a Cochran−Mantel−
Haenszel test stratiﬁ ed by study.
Evaluation of primary cause of death
Th e primary cause of death for all recorded fatalities was 
independently adjudicated by a Mortality Adjudication 
Committee (MAC) that was blinded to treatment. A 
full list of the safety analyses carried out can be found 
in Appendix 1 (see the online supplement). Th is com-
mittee was comprised of two experts in pulmonology 
(L.M.G., D.E.N.) and one in cardiology (S.M.) not linked 
to any of the phase III pivotal studies. Th e committee 
followed similar principles to those previously reported 
(15).
Th e MAC systematically assessed all reported fatali-
ties at the Verbatim Term/PT level. Details of the MAC-
adjudication process, principles of operation, and copies 
of the forms associated with adjudication can be found 
in Appendices 2–5 (see the online supplement).
Following MAC adjudication of all fatalities within 
the studies, the MAC-adjudicated primary cause of 
death and the AEs recorded as having a fatal outcome on 
the case report form by study investigators were com-
pared at the level of the MedDRA SOC and PT.
Vital signs and laboratory monitoring
During the course of these studies, vital signs (heart 
rate and blood pressure), physical examinations, clini-
cal laboratory testing (clinical chemistry, hematology, 
and urinalysis), and pre-dose ECGs were monitored. 
Olodaterol exposure for patients within each group was 
assessed using plasma concentration monitoring, pooled 
for Studies 1222.11, 1222.12, 1222.13, and 1222.14, and 
reported per therapy. Serum potassium was analyzed as 
a systemic pharmacodynamic end point, assessed both 
pre-dose and 1 and 3 hours post-dose at weeks 6 and 
12. In addition, selective safety evaluations included 
ECGs pre-dose and 40 minutes post-dose in all patients 
(weeks 0, 6, 12, 24, and 48) and 24-hour Holter monitor-
ing in a subset of 775 patients (weeks 0, 12, 24, 40, and 
48).
Results
In total, 3104 patients with COPD (2377 male; 727 
female) were included in this pre-deﬁ ned pooled safety 
analysis (Table 1). Th e mean drug exposure for olodat-
erol 5 μg and 10 μg groups was 308.4 and 304.7 days, 
respectively, and 287.5 and 299.0 days for the placebo 
and formoterol groups, respectively. Overall, 18.0% of 
patients discontinued prematurely, with a higher rate 
reported for placebo compared to active treatment: 
22.5% with placebo, 15.1% with olodaterol 5 μg, 16.5% 
with olodaterol 10 μg, and 18.0% with formoterol.
Co-medications and co-morbidities in the 48-week 
studies in COPD were balanced across all groups at 
screening (Table 1). At baseline, 45.4% of patients were 
receiving inhaled corticosteroids, 23.8% were receiving 
LAMAs, and 24.9% were receiving SAMAs; 65.1% of the 
population were receiving cardiovascular medication, 
with 24.0% having co-morbid cardiac disorders and 
33.0% with hypertension.
AEs, serious AEs, and treatment-related AEs
Incidence of AEs was generally balanced across groups, 
with an overall incidence of 71.2% (Table 2 and Appen-
dix 6 [see the online supplement]). Th e majority of AEs 
were respiratory, thoracic, and mediastinal disorders, and 
infections and infestations; only three AE PTs occurred 
with a frequency >5%, namely COPD (representing 
exacerbations and disease worsening), upper respiratory 
tract infection, and nasopharyngitis (Figure 2).
Total serious AEs were also balanced across treat-
ment groups (Table 2). Overall incidence was 16.1% 
and was comparable between all treatment groups for 
the majority of SOCs; the most frequent were reported 
as respiratory, thoracic, and mediastinal disorders, 
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 followed by infections and infestations. A numerically 
higher incidence of neoplasms as serious AEs was seen 
with all active treatments (highest with 10 μg) compared 
to placebo. Th e most frequent type of malignant neo-
plasm observed was lung cancer. Th ere were 53 (1.7%) 
on-treatment deaths recorded during the course of the 
48-week studies (Table 2). Th e most frequent of these 
were due to COPD exacerbations and cardiac and vas-
cular disorders. 
Vital status follow-up identiﬁ ed 21 deaths that occurred 
post-treatment or post-study (solicited) and two deaths 
were recorded post-study without  solicitation (10 in the 
Table 1. Demographic and baseline patient characteristics by treatment group for 48-week, parallel-group trials (treated patient population)
Placebo Olodaterol 5 μg Olodaterol 10 μg Formoterol
Patients, n (%) 885 (100.0) 876 (100.0) 883 (100.0) 460 (100.0)
Sex, n (%)
 Male
 Female
679 (76.7)
206 (23.3)
666 (76.0)
210 (24.0)
661 (74.9)
222 (25.1)
371 (80.7)
89 (19.3)
Mean (SD) age, years 64.3 (8.3) 64.0 (8.7) 64.2 (8.9) 64.9 (8.4)
Smoking status, n (%)
 Ex-smoker
 Current smoker
549 (62.0)
336 (38.0)
547 (62.4)
329 (37.6)
557 (63.1)
326 (36.9)
305 (66.3)
155 (33.7)
Post-bronchodilator screening
 Mean (SD) FEV1, L
 Mean (SD) FEV1 (% predicted), L
1.38 (0.52)
50.0 (15.7)
1.39 (0.50)
51.0 (15.0)
1.37 (0.51)
49.7 (15.1)
1.40 (0.49)
51.8 (15.2)
GOLD, n (%)
 1 (≥80%)
 2 (50–<80%)
 3 (30–<50%)
 4 (<30%)
2 (0.2)
449 (50.7)
326 (36.8)
108 (12.2)
2 (0.2)
451 (51.5)
341 (38.9)
82 (9.4)
1 (0.1)
415 (47.0)
387 (43.8)
80 (9.1)
3 (0.7)
247 (53.7)
172 (37.4)
38 (8.3)
Medication at baseline, %
 Inhaled steroids
 LABA
 SAMA
 LAMA
 Xanthines
 Any cardiovascular medication
β-blockera
46.0
35.7
24.9
23.6
15.0
63.4
10.5
45.0
35.6
25.0
22.1
16.2
66.9
 9.6
45.1
38.4
22.8
24.8
14.8
65.3
9.9
45.7
37.6
28.9
25.4
17.4
64.6
 7.5
Selected co-morbidities at baseline, %
 Cardiac disorders
  Cardiac arrhythmia
  Coronary artery disease
 Other preferred terms of interest
  Hypertension
  Diabetes
  History of neoplasms
23.1
13.0
 9.4
31.4
 4.2
 6.2
25.0
13.6
11.6
36.3
 5.5
 9.2
25.9
13.1
12.3
34.1
 4.4
 7.2
20.0
 9.1
 9.8
27.6
 5.4
 2.8
aPlacebo: n = 856; olodaterol 5 μg: n = 847; olodaterol 10 μg: n = 855; formoterol: n = 453.
SD = standard deviation; FEV1 = forced expiratory volume in 1 second; GOLD = Global initiative for chronic Obstructive Lung Disease; LABA = long-acting β2-agonist; SAMA = short-acting 
muscarinic antagonist; LAMA = long-acting muscarinic antagonist.
Table 2. Overview of AEs for all 48-week, olodaterol parallel-group trials
Placebo
(n = 885)
Olodaterol 5 μg
(n = 876)
Olodaterol 10 μg
(n = 883)
Formoterol
(n = 460)
Patients with any AE, n (%) 627 (70.8) 622 (71.0) 642 (72.7) 318 (69.1)
 Investigator-deﬁ ned related AEs 79 (8.9) 63 (7.2) 52 (5.9) 52 (11.3)
 AEs leading to discontinuation of study drug 74 (8.4) 54 (6.2) 66 (7.5) 37 (8.0)
 Serious AEs 145 (16.4) 138 (15.8) 147 (16.6) 69 (15.0)
  Fatal (on treatment) AEs 13 (1.5) 13 (1.5) 17 (1.9) 10 (2.2)
  Immediately life-threatening 9 (1.0) 6 (0.7) 9 (1.0) 6 (1.3)
  Disability/incapacity 1 (0.1) 1 (0.1) 4 (0.5) 3 (0.7)
  Requires hospitalization 128 (14.5) 122 (13.9) 132 (14.9) 52 (11.3)
  Prolongs hospitalization 5 (0.6) 4 (0.5) 9 (1.0) 3 (0.7)
  Other 13 (1.5) 11 (1.3) 10 (1.1) 8 (1.7)
A patient may be counted in >1 seriousness criterion.
AE = adverse event.
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placebo group, six with olodaterol 5 μg, four with olodat-
erol 10 μg, and three with formoterol [see Appendix 7 in 
the online supplement]). Th is gave a total of 76 deaths. 
More than 98% of patients had satisfactory vital status 
follow-up across the 48-week trials. Incidences of fatal 
AEs reported were comparable between groups.
Treatment-related AEs were also comparable 
between all groups, including respiratory and cardiac 
disorders (Appendix 8 [see the online supplement]). 
COPD and cough were the most frequently described 
AEs, with only small diﬀ erences noted in frequencies 
between treatment groups.
Primary cause of death
All 53 on-treatment deaths underwent external, inde-
pendent adjudication by the MAC to determine the 
primary cause of death (Table 3 and Appendix 7 [see the 
online supplement]).
MAC primary cause of death assessment was in 
complete concordance with 35 (66%) fatal AEs reported 
by the site investigators; both incomplete concordance 
(disagreement at either SOC or PT level) and com-
plete disagreement (at both levels) were reported in 
nine cases (17%) each. Th e level of concordance was 
83% between MAC-determined cause of death and 
site investigator-determined AE leading to death at the 
level of SOC and 70% at the level of PT. For the eight 
(15%) fatal AEs reported as cardiac disorders by the 
study investigators, primary causes of death assessed 
by the MAC were: COPD exacerbation (n = 3), 
unknown cause of death (n  =  3), and sudden cardiac 
death (n = 2).
Figure 2. AEs ≥2% in olodaterol 48-week studies in chronic obstructive pulmonary disease. On-treatment including 12-day washout period unless speciﬁ ed otherwise. 
AE = adverse event; GI = gastrointestinal.
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Table 3. Fatal AEs, adjudicated cause 48-week studies in COPD (on-treatment)
Placebo
(n = 885)
Olodaterol 5 μg
(n = 876)
Olodaterol 10 μg
(n = 883)
Formoterol
(n = 460)
Total with AEs leading to death, n (%) 13 (1.5) 13 (1.5) 17 (1.9) 10 (2.2)
 Respiratory, thoracic, and mediastinal disorders: COPD exacerbation  4 (0.5)  9 (1.0)  4 (0.5)  3 (0.7)
 Infections and infestations: pneumonia 0 0  2 (0.2) 0
  Cardiac and vascular disorders including sudden death: sudden 
death/cardiac death, congestive heart failure, cerebrovascular 
accident, aortic aneurysm/rupture
 6 (0.7)  2 (0.2)  1 (0.1)  4 (0.9)
 Neoplasms: lung, larynx, esophagus, bladder, or hepatic cancer 0  2 (0.2)  7 (0.8)  1 (0.2)
 Death, unknown cause  3 (0.3) 0  2 (0.2)  1 (0.2)
 Other: suicide, arthropod bite 0 0  1 (0.1)  1 (0.2)
AE = adverse event; COPD = chronic obstructive pulmonary disease.
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ECG and Holter monitoring and other safety parameters
Overall, there were no clinically signiﬁ cant changes 
associated with active treatment for any of the six ECG 
parameters (QT interval, QT interval corrected according 
to Bazett’s formula, QT interval with Fridericia correction, 
heart rate, PR interval, and QRS interval) and seven ECG 
abnormalities investigated (ST segment, T wave, U wave, 
rhythm, myocardial infarction, ECG conduction, and 
morphology [see Appendix 1 in the online supplement for 
parameter details]). Likewise, in the subset of patients in 
which Holter-ECG evaluation was carried out, analysis of 
results identiﬁ ed no clinically relevant dose-related eﬀ ect 
or eﬀ ect at any speciﬁ c time point in heart rate, supraven-
tricular premature beats, or ventricular premature beats.
Although small diﬀ erences were noted between 
groups in terms of changes in blood pressure and pulse 
rate, frequencies of increases and decreases were gener-
ally similar between all active treatments and placebo, 
with no discernible trend.
Compared to placebo, a higher proportion of patients 
in the active treatment groups had a shift in maximum 
creatinine phosphokinase to exceed the upper limit of 
normal: 14.1% and 17.7% of patients receiving olodaterol 
5 and 10 μg, respectively, 21.4% receiving formoterol, 
and 8.2% on placebo. Th ere was no diﬀ erence in the 
pattern of AEs in those patients who had a shift in cre-
atinine phosphokinase to greater than the upper limit 
of normal versus the overall population. No relation-
ship between the plasma concentration of olodaterol 
and potassium was observed, and no diﬀ erences were 
reported between treatment groups.
Cardiovascular AE proﬁ le
Incidence of MACE
Incidences of MACE were balanced across treatment 
groups: placebo, 24/885 (2.7%); olodaterol 5 μg, 10/876 
(1.1%); olodaterol 10 μg, 16/883 (1.8%); formoterol, 
9/460 (2.0%) (Table 4). In total, 59 patients experienced 
fatal and non-fatal MACE during the course of the 
48-week studies. Of these, 16 patients had fatal MACE, 
with four additional patients having events coded to 
death due to an unknown origin. Of the 59  MACE, 
29 events were coded to the SMQ end point of ischemic 
heart disease, sub-SMQ myocardial infarction (broad) 
(any); incidences of these were also similar between 
treatment groups (Table 4).
Cardiovascular AEs and sub-group analyses
Within the whole patient population, incidence of “car-
diac disorders” and “vascular disorders” was compara-
ble with olodaterol and placebo (Table 5). Hypertension 
was the only individual cardiac or vascular PT occurring 
at an incidence of >2%, experienced by 3.4%, 2.6%, 2.9%, 
and 1.7% of patients in the placebo, olodaterol 5  μg, 
olodaterol 10 μg, and formoterol groups, respectively. 
Serious AEs were reported infrequently, with no indi-
vidual term occurring at an incidence of >2%. Numeri-
cal diﬀ erences were observed for atrial ﬁ brillation and 
myocardial infarction. Atrial ﬁ brillation was reported in 
0.3% (n = 3), 0.6% (n = 5), 0.6% (n = 5), and 0.2% (n = 1), 
while myocardial infarction was reported in 0.2% (n = 2), 
0.1% (n = 1), 0.5% (n = 4), and in 0 patients receiv-
ing placebo, olodaterol 5 μg, olodaterol 10 μg, and 
Table 4. Frequency of patients with MACE by treatment group in all 48-week studies
Placebo
(n = 885)
Olodaterol 5 μg 
(n = 876)
Olodaterol 10 μg
(n = 883)
Formoterol
(n = 460)
Death (fatal AE) 13 (1.5) 13 (1.5) 17 (1.9) 10 (2.2)
Fatal MACE (including death unknown)  8 (0.9)  3 (0.3)  3 (0.3)  6 (1.3)
 Cardiac disorders SOC (fatal)  3 (0.3)  2 (0.2)  1 (0.1)  3 (0.7)
 Vascular disorders SOC (fatal)  1 (0.1)  0 (0.0)  0 (0.0)  1 (0.2)
 SMQ ischemic heart disease sub-SMQ myocardial infarction (broad; any)  1 (0.1)  0 (0.0)  0 (0.0)  1 (0.2)
 Stroke (PV)  1 (0.1)  0 (0.0)  0 (0.0)  0 (0.0)
 Sudden death (PT)  1 (0.1)  0 (0.0)  0 (0.0)  1 (0.2)
 Cardiac death (PT)  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
 Sudden cardiac death (PT)  0 (0.0)  1 (0.1)  1 (0.1)  0 (0.0)
 Death (PT)  2 (0.2)  0 (0.0)  1 (0.1)  1 (0.2)
Any MACE 24 (2.7) 10 (1.1) 16 (1.8)  9 (2.0)
 Cardiac disorders SOC (fatal)  3 (0.3)  2 (0.2)  1 (0.1)  3 (0.7)
 Vascular disorders SOC (fatal)  1 (0.1)  0 (0.0)  0 (0.0)  1 (0.2)
 SMQ ischemic heart disease sub-SMQ myocardial infarction (broad; any)  9 (1.0)  4 (0.5) 12 (1.4)  4 (0.9)
 Stroke (PV) 11 (1.2)  3 (0.3)  3 (0.3)  1 (0.2)
 Sudden death (PT)  1 (0.1)  0 (0.0)  0 (0.0)  1 (0.2)
 Cardiac death (PT)  0 (0.0)  0 (0.0)  0 (0.0)  0 (0.0)
 Sudden cardiac death (PT)  0 (0.0)  1 (0.1)  1 (0.1)  0 (0.0)
MACE = major adverse cardiac event; AE = adverse event; SOC = System Organ Class; SMQ = Special MedDRA Query; PV = pharmacovigilance (sponsor-deﬁ ned end point); PT = Preferred Term.
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 formoterol, respectively. “Cardiac arrhythmias” was the 
most frequently reported category of cardiovascular 
system adverse event as assessed by (aggregated) SMQ 
and predeﬁ ned sponsor-customized MedDRA queries, 
reported by 145 patients in total, with no diﬀ erences 
between treatment groups (Table 5).
Analysis of the subgroup of patients with cardiac his-
tory revealed a higher incidence of AEs overall (Table 6) 
versus those with no history and, unsurprisingly, a 
higher total incidence of cardiac AEs. Cardiac AEs were 
similar between groups, and all conﬁ dence intervals 
(CIs) included one; however, analysis of the rate ratios 
of respective incidence rates per 100 patient-years of 
events in both olodaterol treatment groups versus pla-
cebo revealed no statistically signiﬁ cant diﬀ erences in 
risk of any cardiac or cardiovascular AE. Risk ratio with 
olodaterol 5 μg versus placebo was 0.97 (95% CI 0.70, 
1.36) for “cardiac disorders” and 1.01 (95% CI 0.68, 1.51) 
for “vascular disorders”, and 0.90 (95% CI 0.64, 1.27) 
and 0.91 (95% CI 0.60, 1.36), respectively, for olodaterol 
10 μg versus placebo.
Similar results were seen in the subgroup of patients 
receiving β-blockers during the trial. A higher incidence 
of AEs was reported versus those who were not taking 
β-blockers (Table 7), largely distributed over various 
organ classes and balanced across treatment groups. 
Cardiac AEs were not increased with olodaterol 5 or 
10  μg versus placebo. In addition, no increase in risk 
estimates of fatal or any MACE end points was observed 
in the cardiac history subgroup with olodaterol versus 
placebo (Appendix 9 [see the online supplement]).
Discussion
In this pooled analysis of 3104 patients from four 
phase  III pivotal studies, we sought to determine the 
safety of the novel once-daily LABA olodaterol via the 
Respimat® inhaler over 48 weeks in patients with mod-
erate to very severe COPD, based on evaluation of AEs, 
laboratory assessments, vital signs, and 12-lead ECG for 
all patients. Vital status follow-up was requested and 
planned to ensure a more robust approach for analysis 
of fatalities by recording any potential inﬂ uence of a 
 diﬀ erential discontinuation bias. 
Incidence of AEs, serious AEs, and on-treatment 
deaths was balanced between olodaterol, active 
Table 5. Frequency of patients with AEs related to the cardiovascular system in all 48-week studies
Placebo
(n = 885)
Olodaterol 5 μg
(n = 876)
Olodaterol 10 μg
(n = 883)
Formoterol
(n = 460)
AEs by SOC/PT in >2% of patients, n (%)
 Cardiac disorders 67 (7.6) 69 (7.9) 64 (7.2) 26 (5.7)
 Vascular disorders 47 (5.3) 50 (5.7) 45 (5.1) 18 (3.9)
  Hypertension 30 (3.4) 23 (2.6) 26 (2.9)  8 (1.7)
Serious AEsa, n (%)
 Cardiac disorders 26 (2.9) 19 (2.2) 17 (1.9)  7 (1.5)
 Vascular disorders  8 (0.9)  8 (0.9)  5 (0.6)  4 (0.9)
Cardiovascular system events in >2% of patients
 SMQ cardiac arrhythmias – sub-SMQ cardiac arrhythmia terms 37 (4.2) 49 (5.6) 39 (4.4) 20 (4.3)
 SMQ cardiac arrhythmias – sub-SMQ cardiac tachyarrythmias 30 (3.4) 31 (3.5) 26 (2.9) 15 (3.3)
 Palpitationsb 13 (1.5) 14 (1.6) 19 (2.2) 10 (2.2)
 SMQ cardiac arrhythmias – sub-SMQ ventricular tachyarrythmias  9 (1.0) 17 (1.9) 12 (1.4)  9 (2.0)
aNo PTs occurred at an incidence >2%; bpredeﬁ ned sponsor-customized MedDRA query.
Utilizing MedDRA SOC and PT classiﬁ cation as well as SMQ and predeﬁ ned sponsor-customized MedDRA queries.
AE = adverse event; SOC = System Organ Class; PT = Preferred Term; SMQ = Special MedDRA Query; MedDRA = Medical Dictionary for Regulatory Activities.
Table 6. Incidence of cardiac and vascular AEs and serious AEs in patients with cardiac disorder at baseline or cardiac history
Cardiac history No cardiac history
Placebo Olodaterol 5 μg Olodaterol 10 μg Formoterol Placebo Olodaterol 5 μg Olodaterol 10 μg Formoterol
Patients, n 204 219 229 92 681 657 654 368
Total AEs, n (%) 152 (74.5) 162 (74.0) 185 (80.8) 66 (71.7) 475 (69.8) 460 (70.0) 457 (69.9) 252 (68.5)
 Cardiac disorders  23 (11.3)  34 (15.5)  31 (13.5) 12 (13.0)  44 (6.5)  35 (5.3)  33 (5.0)  14 (3.8)
 Vascular disorders  15 (7.4)  21 (9.6)  20 (8.7)  6 (6.5)  32 (4.7)  29 (4.4)  25 (3.8)  12 (3.3)
Total serious AEs, n (%)  35 (17.2)  43 (19.6)  44 (19.2) 17 (18.5) 110 (16.2)  95 (14.5) 103 (15.7)  52 (14.1)
 Cardiac disorders  10 (4.9)  12 (5.5)   8 (3.5)  6 (6.5)  16 (2.3)   7 (1.1)   9 (1.4)   1 (0.3)
 Vascular disorders   4 (2.0)   5 (2.3)   3 (1.3)  1 (1.1)   4 (0.6)   3 (0.5)   2 (0.3)   3 (0.8)
AE = adverse event.
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 comparator, and placebo, with the characteristics and 
observed frequencies consistent with those expected 
for a 1-year COPD clinical trial (16,17). As would be 
anticipated in this patient population, the most frequent 
AEs were in the respiratory, thoracic, and mediastinal 
disorders categories, with a similar incidence across 
treatment groups. Cardiovascular AEs including MACE 
were reported less frequently, with comparable inci-
dences across groups. Numerically lower values were 
observed in the olodaterol-treated population.
Given the pharmacologic properties of LABAs, 
there is a potential risk of serious adverse cardiovascu-
lar eﬀ ects (18); furthermore, there is a risk of serious 
exacerbations of asthma and asthma-related deaths in 
patients with asthma (19). Th erefore, detailed investi-
gation of adverse cardiovascular and respiratory safety 
signals is of particular importance when evaluating the 
beneﬁ t:risk ratio for a novel LABA.
In addition to safety data gathered during the course of 
individual clinical trials, it is important to gain a detailed 
understanding of the long-term safety of new therapies 
by in-depth analysis of the total available safety database 
across trials. Th ese data are vital, not only to satisfy drug 
developmental and regulatory requirements (12,13), 
but also to ensure the availability of an adequate bank 
of evidence for practicing clinicians that is suﬃ  ciently 
representative of their patient population to assist them 
in making informed treatment decisions.
Th is pre-speciﬁ ed pooled analysis of the four pivotal 
48-week olodaterol trials represents a rigorous and 
comprehensive safety evaluation for a new LABA, and 
provides robust evidence for the long-term safety of 5 μg 
olodaterol once daily, the submitted and registered dose 
for clinical use, as well as a higher dose of 10 μg, in a 
large population of patients (n = 3104) with moderate to 
very severe COPD. In addition, a relatively high propor-
tion of the population had very severe COPD (GOLD 4: 
8.3–12.2%), with 82.2% having one or more co-morbid-
ities and over two-thirds were receiving cardiovascular 
medication. Th is represents a patient proﬁ le similar to 
patients treated in clinical practice (20,21). It should, 
however, be borne in mind that given the exclusion 
criteria, our data do not apply to patients with recent 
myocardial infarction or unstable/life-threatening car-
diac arrhythmia.
Evaluation of the pooled olodaterol and active-com-
parator results from Studies 1222.13 and 1222.14 dem-
onstrates a similar safety proﬁ le for olodaterol in com-
parison to formoterol, an established twice-daily LABA. 
Th ese data are in line with the individual ﬁ ndings of the 
constituent trials of this analysis, plus those of the wider 
phase III clinical program (6,7,9,10).
Overall, the incidence of on-treatment fatal events 
reported here (1.7%) was consistent with that expected 
for a 1-year trial in a patient population with moderate 
to very severe COPD. Although not directly compa-
rable, it was also in line with those reported for tiotro-
pium Respimat® in two 1-year studies (22) and lower 
than the overall annualized death rates for other large 
COPD trials, which ranged from an average of 2.6% in 
the TIOSPIR study (mean follow-up 2.3 years) (23) to 
3.9% in the 4-year UPLIFT study (24) and 4.7% in the 
3-year TORCH study (25).
Th e causes of fatal AEs determined in the 48-week 
“on-treatment” population were similar across treat-
ment groups. During the olodaterol pivotal studies, 
investigators were asked to record all on-treatment AEs 
as well as identifying the outcome of the event (one 
option being “fatal”). In the pooled analysis, all deaths 
across the four pivotal studies underwent a further 
independent assessment by an external MAC of three 
physicians to ascertain the primary cause of death. 
Independent adjudication of primary cause of death by 
committee can provide valuable additional detail to aid 
in the better understanding of on-treatment fatalities 
(15,23,26,27). 
Due to the complex sequence of AEs that can occur at 
the time of a fatal event, and to minimize between-site 
variation in determination of cause of death, the utiliza-
tion of a standardized and predeﬁ ned approach to cause 
of death determination by an independent committee 
blinded to treatment allocation was considered to be 
important. Th is approach also allowed assignment of 
a unique cause of death per patient, rather than poten-
tially several AEs leading to death, as assigned by the site 
investigator.
Table 7. Incidence of cardiac and vascular AEs and serious AEs in concomitant β-blocker medication subgroup
Concomitant β-blocker medication No concomitant β-blocker medication
Placebo Olodaterol 5 μg Olodaterol 10 μg Formoterol Placebo Olodaterol 5 μg Olodaterol 10 μg Formoterol
Patients, na 90 81 85 34 766 766 770 419
Total AEs, n (%) 71 (78.9) 65 (80.2) 70 (82.4) 28 (82.4) 553 (72.2) 552 (72.1) 568 (73.8) 288 (68.7)
 Cardiac disorders 23 (25.6) 17 (21.0) 19 (22.4)  7 (20.6)  44 (5.7)  50 (6.5)  45 (5.8)  19 (4.5)
 Vascular disorders  9 (10.0) 12 (14.8)  9 (10.6)  4 (11.8)  38 (5.0)  38 (5.0)  36 (4.7)  14 (3.3)
Total serious AEs, n (%) 27 (30.0) 23 (28.4) 21 (24.7)  6 (17.6) 118 (15.4) 115 (15.0) 126 (16.4)  63 (15.0)
 Cardiac disorders 11 (12.2)  8 (9.9) 10 (11.8)  4 (11.8)  15 (2.0)  11 (1.4)   7 (0.9)   3 (0.7)
 Vascular disorders  2 (2.2)  3 (3.7)  2 (2.4)  2 (5.9)   6 (0.8)   5 (0.7)   3 (0.4)   2 (0.5)
aOnly patients with non-missing values for β-blocker use at baseline were included.
AE = adverse event.
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Although the overall incidence of neoplasms was 
within the range of that typically reported for a COPD 
population (25,28), there were few cases with placebo 
and more with olodaterol 10 μg and formoterol than 
with olodaterol 5 μg. An association of lung cancer with 
LABA treatment has not been reported in the literature 
and preclinical studies of olodaterol suggested no evi-
dence for carcinogenic potential.
Th roughout its development program, olodaterol was 
administered via the Respimat® inhaler, a propellant-free 
inhaler that uses mechanical force to provide a metered 
dose of medication as a Soft Mist™ (29). Th us, olodat-
erol delivered via the Respimat® inhaler provides an 
additional element of choice for physicians prescribing 
bronchodilators, potentially allowing optimization of 
treatment for individual patients. Recently, the safety of 
tiotropium delivered via Respimat® has been compared 
to delivery through a dry powder inhaler in a large trial 
of 17 135 patients (TIOSPIR). In this study, tiotropium 
5 μg delivered via Respimat® and tiotropium 18 μg deliv-
ered via HandiHaler® had comparable risks of death and 
ﬁ rst exacerbation.
Th e present analysis represents a valuable addition 
to the growing evidence base for the safety of LABAs 
in COPD, reporting no clinically relevant, dose-related 
adverse safety signals or patterns in an extensive array 
of diﬀ erent parameters during ECG and Holter moni-
toring associated with olodaterol, along with similar 
incidences of cardiovascular AEs when compared to 
placebo and formoterol in the general trial population. 
Th e frequency of cardiovascular AEs, including MACE, 
across treatments was similar in subgroups of patients 
with a history of cardiac disease and in those who were 
taking β-blockers.
Conclusions
Th ese data provide robust, comprehensive evidence for 
the long-term safety and tolerability of once-daily olo-
daterol 5 and 10 μg delivered via Respimat® in a large 
population of patients with moderate to very severe 
COPD, including those with a history of cardiovascular 
disease or β-blocker use and patients with very severe 
COPD on multiple concomitant medications. Although 
the risk:beneﬁ t ratio was considered positive for both 
5 and 10 μg olodaterol, 5 μg was selected as the dose 
for submission and has been registered in more than 
30 countries worldwide, including, more recently, the 
United States.
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